A carregar...
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
BACKGROUND: Lung cancer is still the main cause of cancer death worldwide despite the availability of targeted therapies and immune-checkpoint inhibitors combined with chemotherapy. Cancer cell heterogeneity and primary or acquired resistance mechanisms cause the elusive behaviour of this cancer and...
Na minha lista:
| Publicado no: | J Exp Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6570906/ https://ncbi.nlm.nih.gov/pubmed/31200752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1199-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|